Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects
A Double-blind, Placebo-controlled, Randomized, First-in-human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MYMD1 Capsules in Healthy Male Adult Subjects
Sponsor: TNF Pharmaceuticals, Inc.
A PHASE1 clinical study on Undefined, this trial is completed. The trial is conducted by TNF Pharmaceuticals, Inc. and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — May 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TNF Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .